Literature DB >> 10969768

Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region.

M A Brantley1, J W Harbour.   

Abstract

Uveal melanoma is the most common malignancy of the eye, but little is known about its underlying genetic defects. Melanomas of uveal origin, unlike those of the skin, are rarely familial and have not been linked consistently to mutations in tumor suppressor genes. Here, we investigated the Rb pathway in uveal melanoma. Most tumors displayed strong immunostaining for Rb and p16, suggesting that they were not mutationally inactivated. However, Rb was frequently phosphorylated at serine-807 and serine-811, and cyclin D1 was expressed in many of the tumors. Mutation of these serine residues prevented cyclin D-dependent phosphorylation from inactivating Rb in cultured cells. We conclude that Rb is frequently inactivated in uveal melanoma by phosphorylation of residues in the COOH-terminal region that regulate its activity, and one mechanism for this phosphorylation is overexpression of cyclin D.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969768      PMCID: PMC5395201     

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  CDK inhibitors: positive and negative regulators of G1-phase progression.

Authors:  C J Sherr; J M Roberts
Journal:  Genes Dev       Date:  1999-06-15       Impact factor: 11.361

2.  Growth suppression by an E2F-binding-defective retinoblastoma protein (RB): contribution from the RB C pocket.

Authors:  L L Whitaker; H Su; R Baskaran; E S Knudsen; J Y Wang
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

3.  Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.

Authors:  A S Lundberg; R A Weinberg
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

4.  Differential expression of G1 cyclins and cyclin-dependent kinase inhibitors in normal and transformed melanocytes.

Authors:  F Mouriaux; F Casagrande; M J Pillaire; S Manenti; F Malecaze; J M Darbon
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-05       Impact factor: 4.799

5.  Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors.

Authors:  D Parry; D Mahony; K Wills; E Lees
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

6.  Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma.

Authors:  S L Merbs; D Sidransky
Journal:  Invest Ophthalmol Vis Sci       Date:  1999-03       Impact factor: 4.799

7.  A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988.

Authors:  M Diener-West; B S Hawkins; J A Markowitz; A P Schachat
Journal:  Arch Ophthalmol       Date:  1992-02

8.  Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.

Authors:  M Ohta; H Nagai; M Shimizu; D Rasio; D Berd; M Mastrangelo; A D Singh; J A Shields; C L Shields; C M Croce
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

9.  Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.

Authors:  M Ohta; D Berd; M Shimizu; H Nagai; M Mastrangelo; J A Shields; C L Shields; C M Croce; K Huebner
Journal:  Int J Cancer       Date:  1996-03-15       Impact factor: 7.396

10.  Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.

Authors:  N Soufir; B Bressac-de Paillerets; L Desjardins; C Lévy; J Bombled; I Gorin; P Schlienger; D Stoppa-Lyonnet
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more
  18 in total

Review 1.  Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.

Authors:  James W Mandell
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

Review 2.  Eye cancer: unique insights into oncogenesis: the Cogan Lecture.

Authors:  J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

Review 3.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

4.  Limited redundancy in phosphorylation of retinoblastoma tumor suppressor protein by cyclin-dependent kinases in acute lymphoblastic leukemia.

Authors:  Nicole M R Schmitz; Andreas Hirt; Markus Aebi; Kurt Leibundgut
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

5.  Deregulation of the Rb and p53 pathways in uveal melanoma.

Authors:  M A Brantley; J W Harbour
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 6.  Molecular pathology of uveal melanoma.

Authors:  S E Coupland; S L Lake; M Zeschnigk; B E Damato
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

Review 7.  Emerging insights into the molecular pathogenesis of uveal melanoma.

Authors:  Solange Landreville; Olga A Agapova; J William Harbour
Journal:  Future Oncol       Date:  2008-10       Impact factor: 3.404

Review 8.  Malignant melanoma in the 21st century: the emerging molecular landscape.

Authors:  Aleksandar Sekulic; Paul Haluska; Arlo J Miller; Josep Genebriera De Lamo; Samuel Ejadi; Jose S Pulido; Diva R Salomao; Erik C Thorland; Richard G Vile; David L Swanson; Barbara A Pockaj; Susan D Laman; Mark R Pittelkow; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2008-07       Impact factor: 7.616

9.  Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.

Authors:  L M Neri; A Cani; A M Martelli; C Simioni; C Junghanss; G Tabellini; F Ricci; P L Tazzari; P Pagliaro; J A McCubrey; S Capitani
Journal:  Leukemia       Date:  2013-07-29       Impact factor: 11.528

10.  Oncogenic mutations in GNAQ occur early in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Long; Shenghui Duan; M Laurin Council; Anne M Bowcock; J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-21       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.